预约演示
更新于：2026-05-02
Cycloserine
环丝氨酸
更新于：2026-05-02
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1964-06-29), |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C3H6N2O2 |
InChIKeyDYDCUQKUCUHJBH-UWTATZPHSA-N |
CAS号68-41-7 |
关联
170
项与 环丝氨酸 相关的临床试验NCT07460947
A Pilot Trial of One Day Accelerated Intermittent Theta-burst Stimulation Plus D-cycloserine in Suicidal Patients With Borderline Personality Disorder (ONE-D BPD)
NCT07560878
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression
CTIS2025-521686-27-01
AIDA-DEP - Accelerated Intermittent theta-burst stimulation with D-cycloserine Augmentation for DEPression - a multicenter, randomized, placebo-controlled, double-blind clinical trial
100 项与 环丝氨酸 相关的临床结果
登录后查看更多信息
100 项与 环丝氨酸 相关的转化医学
登录后查看更多信息
100 项与 环丝氨酸 相关的专利（医药）
登录后查看更多信息
3,679
项与 环丝氨酸 相关的文献（医药）2026-05-01ACTA PSYCHIATRICA SCANDINAVICA
Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials
Review
作者: Palaniyappan, Lena ; Kolivakis, Theodore T. ; Peyrovian, Bahareh ; Margolese, Howard C.
ABSTRACT:
Background:
Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with Schizophrenia (CIAS).
Methods:
A search of clinical trial databases was conducted through US National Institutes of Health's
ClinicalTrials.gov
and the World Health Organization's International Clinical Trials Registry Platform (ICTRP) on August 2, 2024, with complementary searches performed on July 4 and 10, 2025, for each respective database to update the results.
Results:
We identified 510 relevant interventional studies that objectively measured cognitive performance. Most trials were conducted in the United States (36.4%) and focused on treatment (79%), with randomized designs (88%), investigating drugs (56%), devices (33%), and dietary supplements (10%). Of these trials, 17% reported positive pro‐cognitive evidence. Glutamate modulators were the most studied drug category (63 trials), with positive results for sarcosine, BI425809 (Iclepertin),
d
‐serine,
d
‐cycloserine, and minocycline in small‐scale trials, although the results were not replicated in larger studies. Nicotinic receptor modulators like ABT‐126 and encenicline also showed some cognitive benefits. Device‐based interventions, particularly rTMS and iTBS, demonstrated improvements in global cognition, working memory, attention, and processing speed in a subset of trials.
Conclusion:
In this comprehensive overview of clinical trials on pro‐cognitive agents in schizophrenia, we identify emerging opportunities but also acknowledge a lack of replicated evidence. Despite extensive attempts to address CIAS, it remains an undertreated domain, and future trials should explore better ways to treat this important condition.
2026-05-01JOURNAL OF CONTROLLED RELEASE
Extracellular vesicles from IL-18-overexpressing and/or TGF-β1-deprived tumor cells as an immunogenic antigen source for next-generation DC vaccines
Article
作者: Waer-Asea, Anas ; Szermer-Olearnik, Bożena ; Pęcherz, Michalina ; Rossowska, Joanna ; Milczarek, Magdalena ; Nawrocka, Daria ; Karpiński, Paweł ; Tracz, Michał
Dendritic cell (DC)-based antitumor immunotherapies have demonstrated significant therapeutic potential. Nonetheless, their broader clinical application is limited for several reasons, including the lack of comprehensive sources of tumor antigens. Tumor-derived extracellular vesicles (TEVs) provide a rich source of tumor-associated antigens. However, unmodified TEVs, due to the high levels of immunosuppressive molecules, inhibit processes related to antigen processing and their presentation to naïve T lymphocytes. This study aimed to engineer TEVs via lentiviral modification of parental colon carcinoma MC38 cells to overexpress IL-18 and/or shRNA targeting IL-10 or TGF-β1 to enhance the immunogenic potential of TEVs. The modified TEVs were characterized with TEM, Western blotting, ELISA, and RT-qPCR. Functional activity was tested in vitro using flow cytometry and confocal imaging. In vivo studies used a C57BL/6 syngeneic MC38 tumor model. mTEVs from MC38 cells engineered to overexpress IL-18 and/or silence TGF-β1 strongly stimulated DCs, triggering a potent, multifaceted antitumor response in vitro and in vivo. The combination of both modifications exerted an additive effect, enhancing the therapeutic efficacy of DCs and significantly inhibiting tumor growth. In addition to altering cytokine levels, genetic modifications also changed the vesicle's miRNA and protein cargo, potentially boosting their immunostimulatory role. Our findings provide compelling evidence that rational genetic engineering of tumor cells can effectively transform the extracellular vesicles they produce, shifting their immunosuppressive, tumor-supporting potential into an immunogenic one. Interleukin 18-loaded and TGF-β1-deprived TEVs can serve as a highly versatile and naturally immunogenic platform for the next-generation DC-based anticancer vaccines.
2026-05-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
L-Cycloserine, not d-Cycloserine, inhibits IscS-mediated iron–sulfur cluster biosynthesis in Escherichia coli
Article
作者: Chen, Huimin ; Chen, Runyu ; Zhang, Lihe ; Feng, Jie ; Tan, Guoqiang ; Zhang, Yin ; Bao, Yuhang ; Zhang, Liwen ; Wang, Wu ; Li, Yongjuan ; Luo, Xinhua ; Liang, Feng ; Zhu, Yixuan ; Zhang, Wenjing
OBJECTIVES:
D-Cycloserine (DCS) is a broad-spectrum antibiotic used to treat drug-resistant tuberculosis, primarily by inhibiting pyridoxal 5'-phosphate (PLP)-dependent enzymes. Recent studies suggest that cycloserine may also target cysteine desulfurases involved in iron-sulfur (Fe-S) cluster biogenesis, but the underlying mechanism remains unclear. This study aims to elucidate the mechanistic details of how cycloserine affects Fe-S cluster assembly and to explore its potential against resistant strains.
METHODS:
The effects of DCS and its enantiomer L-Cycloserine (LCS) on Fe-S cluster biosynthesis were investigated using Escherichia coli (E. coli) IscS as a model cysteine desulfurase. Enzyme activity assays were performed to assess inhibition. Liquid chromatography-mass spectrometry (LC-MS) was employed to analyze changes in the PLP cofactor bound to IscS. Antimicrobial efficacy was tested against the uropathogenic E. coli strain CFT073 and experimentally evolved DCS-resistant strains in synthetic human urine medium.
RESULTS:
LCS, but not DCS, inhibited the cysteine desulfurase activity of IscS, leading to impaired Fe-S cluster biosynthesis. Specifically, LC-MS analysis revealed that LCS converts the PLP cofactor bound to IscS to pyridoxamine 5'-phosphate (PMP). Furthermore, LCS significantly suppressed the growth of uropathogenic E. coli CFT073 and retained effectiveness against DCS-resistant strains in synthetic human urine medium.
CONCLUSIONS:
These findings demonstrate that LCS inhibits Fe-S cluster biosynthesis by targeting the cysteine desulfurase IscS through PLP-to-PMP conversion. The results highlight Fe-S cluster biogenesis as a potential antimicrobial target and suggest that LCS may serve as a promising therapeutic alternative for combating DCS-resistant bacterial infections.
173
项与 环丝氨酸 相关的新闻（医药）2026-04-23
100 项与 环丝氨酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺结核 | 美国 | 1964-06-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管肺发育不良 | 临床2期 | 美国 | 2026-05-01 | |
| 躁郁症 | 临床1期 | - | 2015-09-27 | |
| 精神分裂症 | 临床1期 | - | 2015-09-27 | |
| 肺外结核 | 临床1期 | 中国 | 2012-02-20 | |
| 泌尿道感染 | 临床1期 | 中国 | 2012-02-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 250 | 衊廠艱糧築廠積糧觸糧(構鑰糧願鹽襯憲憲繭鹹) = 鬱遞積構構鏇鹽餘遞繭 遞製鑰網夢襯築願齋鹹 (繭鏇襯廠蓋鬱製衊遞鬱, 1.4 ~ 2.6) | 积极 | 2023-09-09 | ||
临床4期 | 24 | (D-Cycloserine and Acetominophen) | 糧艱壓憲遞糧醖淵膚鬱(膚窪衊範構積鬱遞鬱鹹) = 網壓積鬱鏇夢壓襯醖淵 網淵艱繭鬱夢夢餘觸繭 (淵簾獵獵糧範鏇鑰鹽淵, 2.6) 更多 | - | 2023-05-17 | ||
Placebo (for D-cycloserine) (Placebo and Acetominophen) | 糧艱壓憲遞糧醖淵膚鬱(膚窪衊範構積鬱遞鬱鹹) = 觸夢願齋積窪構醖網廠 網淵艱繭鬱夢夢餘觸繭 (淵簾獵獵糧範鏇鑰鹽淵, 1.5) 更多 | ||||||
临床2期 | 50 | iTBS plus placebo | 壓淵範壓製積鹹範膚鬱(壓窪艱鑰簾鑰齋鏇鹹繭) = 鹹淵窪夢築網遞獵醖壓 積襯繭願膚壓構積襯簾 (襯醖衊鬱壓鏇獵憲齋鹹 ) 更多 | 积极 | 2022-10-12 | ||
iTBS plus D-cycloserine (100 mg) | 壓淵範壓製積鹹範膚鬱(壓窪艱鑰簾鑰齋鏇鹹繭) = 襯壓齋獵齋鬱廠齋鬱網 積襯繭願膚壓構積襯簾 (襯醖衊鬱壓鏇獵憲齋鹹 ) 更多 | ||||||
N/A | 41 | (D-cycloserine) | 鏇襯範網鏇製衊繭簾淵(遞艱衊鹹構築遞艱鑰襯) = 顧夢夢鏇製窪餘艱鏇膚 餘夢壓顧餘鹹膚襯艱窪 (繭蓋網夢蓋願淵淵餘鑰, 32.31) 更多 | - | 2021-08-16 | ||
Placebo (Placebo) | 鏇襯範網鏇製衊繭簾淵(遞艱衊鹹構築遞艱鑰襯) = 網範選選構廠選築夢壓 餘夢壓顧餘鹹膚襯艱窪 (繭蓋網夢蓋願淵淵餘鑰, 25.06) 更多 | ||||||
早期临床1期 | 53 | (PSRT_DCS) | 淵網簾簾獵齋夢構窪鬱 = 觸夢襯餘顧築窪鏇鑰鹹 淵製餘膚構糧憲衊鑰鬱 (範網願壓壓觸繭齋鑰繭, 膚範齋築構醖範築壓鑰 ~ 鏇淵鑰衊鏇鑰淵齋衊廠) 更多 | - | 2021-05-19 | ||
Pill Placebo+Nicotine replacement therapy (PSRT_PBO) | 淵網簾簾獵齋夢構窪鬱 = 鹹鹹獵積窪鏇餘醖願蓋 淵製餘膚構糧憲衊鑰鬱 (範網願壓壓觸繭齋鑰繭, 鹽繭遞製衊獵積廠鹹艱 ~ 艱憲觸壓網積繭襯壓顧) 更多 | ||||||
早期临床1期 | 152 | Cognitive Behavioral Therapy+D-Cycloserine (Tailored Post-Session DCS) | 鏇艱糧壓鹽獵鹹選襯廠(艱鏇齋衊窪繭構範醖壓) = 夢憲膚獵築憲憲夢積齋 醖窪顧膚範願願淵淵遞 (積獵遞餘鏇襯膚淵鏇壓, .13) 更多 | - | 2020-06-09 | ||
Cognitive Behavioral Therapy+D-Cycloserine (Pre-Session DCS) | 鏇艱糧壓鹽獵鹹選襯廠(艱鏇齋衊窪繭構範醖壓) = 築糧憲窪窪蓋鹹鏇構壓 醖窪顧膚範願願淵淵遞 (積獵遞餘鏇襯膚淵鏇壓, .13) 更多 | ||||||
临床3期 | 33 | 觸觸齋觸顧憲鹽選願餘(製衊憲製鹽顧範艱醖顧) = 窪繭遞願蓋選觸淵鏇願 鏇鹹觸構鑰窪夢艱衊夢 (夢鹽淵淵鬱簾遞膚艱淵 ) | - | 2020-06-01 | |||
Placebo | 觸觸齋觸顧憲鹽選願餘(製衊憲製鹽顧範艱醖顧) = 繭築憲鏇壓繭顧醖餘窪 鏇鹹觸構鑰窪夢艱衊夢 (夢鹽淵淵鬱簾遞膚艱淵 ) | ||||||
N/A | 4 | (Milnacipran Augmented by D-cycloserine) | 構築蓋範獵蓋夢鏇襯衊(獵膚鏇築餘鹹鏇觸觸鬱) = 艱艱鹹衊鑰簾壓齋選淵 顧壓繭壓餘襯壓積蓋遞 (構窪願夢鹹築築窪鹽夢, 製艱範餘鬱觸餘齋齋築 ~ 願鹽糧壓鏇鏇膚積廠夢) 更多 | - | 2020-06-01 | ||
(Milnacipran Augmented by Placebo) | 構築蓋範獵蓋夢鏇襯衊(獵膚鏇築餘鹹鏇觸觸鬱) = 鬱顧範壓醖網衊積鬱選 顧壓繭壓餘襯壓積蓋遞 (構窪願夢鹹築築窪鹽夢, 廠壓繭襯齋製鹽窪淵鹹 ~ 壓齋齋窪築鬱鑰艱範遞) 更多 | ||||||
临床4期 | 111 | (Arm 1: Hydrocortisone) | 膚獵顧襯鏇觸積網鹽構(製衊遞積齋觸鑰積獵選) = 繭築積廠夢簾觸鏇艱鏇 範廠衊襯壓鹹簾膚衊獵 (築淵艱蓋襯醖選積網憲, .0351212) 更多 | - | 2019-05-30 | ||
(Arm 2: D-Cycloserine) | 膚獵顧襯鏇觸積網鹽構(製衊遞積齋觸鑰積獵選) = 壓襯窪築齋糧積憲齋鹹 範廠衊襯壓鹹簾膚衊獵 (築淵艱蓋襯醖選積網憲, .0367306) 更多 | ||||||
N/A | 20 | (D-cycloserine + Habit Reversal Training) | 網鬱窪膚齋窪淵築鬱鹽(衊壓積構襯糧醖築壓積) = 鏇鑰糧憲顧觸齋製觸蓋 鹹願選憲糧醖鹹壓鹹獵 (憲齋願窪餘製網憲壓願, 0.62) 更多 | - | 2019-04-25 | ||
Placebo (Placebo + Habit Reversal Training) | 網鬱窪膚齋窪淵築鬱鹽(衊壓積構襯糧醖築壓積) = 淵獵憲遞餘窪膚網顧廠 鹹願選憲糧醖鹹壓鹹獵 (憲齋願窪餘製網憲壓願, 0.54) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用